KARACHI – Health-focused company Haleon has announced a $12 million investment to increase the production of Panadol in Pakistan.
According to Dawn, the project began in 2023 and is expected to be completed by the end of 2026.
The goal is to ensure better availability of this commonly used over-the-counter medicine.
Haleon CEO Qawi Nasir said the company is committed to making healthcare more accessible for people.
He added that since separating from GSK in 2022, Haleon has gained more flexibility to support local innovation and growth.
